Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446730 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL10151427 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL4074539 | 0.92 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL2929834 | 0.92 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL2926494 | 0.92 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL1339459 | 0.92 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL3415474 | 0.92 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL3415478 | 0.92 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL496608 | 0.89 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL24909276 | 0.80 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106215-B2 | 3-aza-bicyclo[3.3.0]octane compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-31 | — | — | US | disclosed |
| EP-2164847-B1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2164847-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009004584-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009004584-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | HCRTR2, HCRTR1, OXTR | NR1H2 237/4885CHRM2 270/4885CHRM1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.